Navigation Links
Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
Date:3/31/2009

d retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicate
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased ... Life Science organizations who need document translations. Clients will ... their documents in advance with a selection of nearly 50 ... often a critical factor in clinical and scientific fields, and ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... loss is a major cause of death from roadside bombs ... for people age 4 to 44, often overwhelms the body,s ... natural process, a team led by Erin Lavik, a new ... doctoral student, James P. Bertram, built synthetic platelets that show ...
... Care at Hahnemann among the Best in the Nation ... it has been granted Magnet(R) recognition by the American Nurses ... the highest levels of recognition a hospital or medical center ... hospitals in the country that have achieved this prestigious distinction. ...
... , , , , WALTHAM, ... world,s leading research and advisory firms for pharmaceutical and ... dermatologists, Centocor Ortho Biotech/Janssen-Cilag,s Stelara and Abbott,s briakinumab (both ... share in 2012 in the drug market for moderate ...
Cached Biology Technology:Researchers take the inside route to halt bleeding 2Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3
(Date:4/23/2014)... contribute to early fetal death according to a new ... Children,s Hospital Los Angeles and Ulaanbaatar, Mongolia the ... paper published today in the journal BMC Pregnancy ... between seasonal ambient air pollutants and pregnancy loss in ... the highest levels of air pollution of all world ...
(Date:4/23/2014)... Like a hungry diner ripping open a dinner roll, ... must tear open a hydrogen molecule. Now researchers have ... the two halves of its hydrogen feast. The view ... make the catalyst work better for alternative energy uses. ... shown precisely where the hydrogen halves end up in ...
(Date:4/23/2014)... research shows that male black widow spiders prefer their ... example of mate preference by male spiders. ... and Maydianne Andrade, a professor in UTSC,s Department of ... the wild that males overwhelmingly chose to mate with ... can tell whether a potential mate is well-fed and ...
Breaking Biology News(10 mins):Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Picky male black widow spiders prefer well-fed virgins 2
... Nadeau, PhD, of Case Western Reserve University School of ... (NIH) Director,s Pioneer Award. One of 17 ... investigate transgenerational genetic effects, where the biological features and ... depend as much on the genetics of ancestral generations ...
... A 15-year experiment in an outdoor "laboratory" on Ohio ... just as many, if not more, ecological services as will ... been comparing the behavior of two experimental marshes on the ... and another that was left to colonize plant and animal ...
... in Spanish . A beneficial yeast that ... the fungal culprit behind Fusarium head blight ("scab"). U.S. ... isolated an improved variant of the yeast Cryptococcus flavescens ... as a biocontrol agent. In susceptible wheat and ...
Cached Biology News:Case Western Reserve geneticist receives prestigious NIH Director's Pioneer Award 2Planted, unplanted man-made wetlands are similar at year 15, and function as effective carbon sinks 2Planted, unplanted man-made wetlands are similar at year 15, and function as effective carbon sinks 3Planted, unplanted man-made wetlands are similar at year 15, and function as effective carbon sinks 4Flower-dwelling yeast licensed for use against scab disease 2